FGFR2 and endometrial cancer: The treatment of FGFR2-driven MFE-296 endometrial cancer cells with the FGFR inhibitor PD173074 was also shown to decrease H3K4me3 and H3K27ac at the PHLDA1 locus, and levels of PHLDA1 in this model were also found to be regulated by a PKC/MAPK-mediated pathway.